Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management

Bulletin du cancer
Marie BretagneFrançois Goldwasser

Abstract

Angiogenesis inhibition is a major antitumor strategy that has emerged during the last decade. Oral tyrosine kinase inhibitors (TKI) targeting the VEGF receptor, including sunitinib, sorafenib, axitinib, regorafenib, pazopanib, and vandetanib reduce tumor growth and metastasis. These agents are approved for the treatment of metastatic diseases in first or second-line. They display a narrow therapeutic index. However, data in the elderly and/or in patients with multiple illnesses remain scarce. This population is classically excluded from clinical trials. The aim of this review is to provide an overview of existing literature regarding antiangiogenic TKI tolerance in the elderly (>70 years old). We also highlight key points of the pre-therapeutic evaluation and summarize the management of common toxicities.

References

Dec 30, 1999·The New England Journal of Medicine·L F HutchinsK S Albain
Jun 5, 2003·Nature Medicine·Napoleone FerraraJennifer LeCouter
Dec 30, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sharyn D BakerAlex Sparreboom
Mar 11, 2005·The New England Journal of Medicine·Dino VeneriEnzo Bonora
Mar 29, 2005·The Oncologist·Matti S AaproMartine Extermann
Jul 5, 2005·The Lancet Oncology·Caroline RobertThierry Le Chevalier
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandrine FaivreEric Raymond
Jun 7, 2006·The Canadian Journal of Cardiology·N A KhanUNKNOWN Canadian Hypertension Education Program
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
May 12, 2007·European Urology·Paul C M S Verhagen
Aug 10, 2007·Journal of the National Cancer Institute·Frank A ScappaticciHerbert Hurwitz
Dec 18, 2007·Lancet·Tammy F ChuMing Hui Chen
Jun 14, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M E LacoutureJ Guitart
Oct 9, 2008·Journal of the National Cancer Institute·Tim EisenUNKNOWN TARGET Study Group
Nov 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dana D Hu-LoweSteve L Bender
Jan 22, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S AntounM B Sawyer
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cora N SternbergRobert E Hawkins
Mar 31, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toni K ChoueiriJoaquim Bellmunt
Mar 31, 2010·Journal of the National Cancer Institute·Michael L MaitlandUNKNOWN Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Dr
Aug 3, 2010·Investigational New Drugs·Stanislas RopertFrançois Goldwasser
Feb 19, 2011·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Jun GeJi-Yan Liu
May 10, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A BamiasM A Dimopoulos
Aug 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arti HurriaWilliam P Tew
Oct 26, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Samuel A WellsMartin J Schlumberger
Jul 4, 2012·The Oncologist·Pascaline Boudou-RouquetteFrançois Goldwasser
Oct 12, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A BrunelloV Zagonel
Dec 12, 2012·International Journal of Cancer. Journal International Du Cancer·Wei-Xiang QiYang Yao
Aug 24, 2013·The New England Journal of Medicine·Robert J MotzerToni K Choueiri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.